FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of... | April 19, 2023

Related Keywords

United States ,Levi Garraway ,Roche Group ,Global Product Development ,Drug Administration ,Genentech ,Lymphoma Study Association ,International Prognostic Index ,Lymphoma Academic Research Organisation ,Global Product ,Lugano Response Criteria ,Prescribing Information ,Important Safety ,Cytokine Release Syndrome ,Epstein Barr Virus ,Important Safety Information ,Serious Side Effects ,Medication Guide ,Roche Holding Ag Stock Exchange ,News ,Information ,Press Release ,Polivy ,Combination ,Us ,The ,First ,Therapy ,N ,Early , 0 ,Tears ,Or ,Treatment ,F ,Diffuse ,Barge ,Aggressive ,Disease ,End ,Most ,Common ,Orm Rog Ch0012032048 ,